Filing Flows › Prelude Therapeutics (PRLD) › Q2 2026
Prelude Therapeutics (PRLD) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 11, 2026
Prelude Therapeutics (PRLD) reported revenue of $5.7M for the second quarter 2026 (Q2 2026) and +25% from the quarter before. Operating margin was -270.9%, net loss $13.9M (244.1% of revenue).
Prelude Therapeutics, Q2 2026: revenue $5.7M, operating margin -270.9%, net loss $13.9M, operating cash flow −$15.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.7M | +25% | — |
| Operating profit | −$15.5M | — | — |
| Net earnings | −$13.9M | — | — |
| Operating cash flow | −$15.6M | — | — |
What changed
Revenue was $5.7M in Q2 2026, up 25% from the previous quarter.
Operating costs exceeded revenue by $15.5M, an operating margin of -270.9%. The quarter ended with a net loss of $13.9M, wider than the previous quarter's $10.4M loss.
Operating cash flow was −$15.6M. Non-cash charges added back $353K of depreciation and amortization and $2.0M of share-based compensation. Working capital and other items used $4.0M.
Questions
What was Prelude Therapeutics' revenue in the second quarter 2026?
Prelude Therapeutics (PRLD) reported revenue of $5.7M for the second quarter 2026 (Q2 2026) and +25% from the quarter before.
Was Prelude Therapeutics profitable in the second quarter 2026?
Operating loss was $15.5M (-270.9% of revenue) and net loss $13.9M.